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Diagnostic journey and impact of enzyme
replacement therapy for mucopolysaccharidosis
IVA: a sibling control study
Can Ficicioglu1* , Dena R. Matalon2, Nicole Luongo1, Caitlin Menello1, Tracy Kornafel1 and Andrew J. Degnan3

Abstract
Background: Mucopolysaccharidosis (MPS) IVA, also known as Morquio A syndrome, is a rare autosomal recessive
lysosomal storage disorder caused by a deficiency in the enzyme N-acetylgalactosamine-6-sulfatase. Early recognition, diagnosis, and treatment of this progressive, multisystem disease by enzyme replacement therapy (ERT) can lead
to improved outcomes and reduced mortality.
Methods: This report documents the diagnostic journey and treatment with ERT of three siblings with MPS IVA.
Clinical outcome measures included growth, endurance, imaging, cardiac, respiratory, ophthalmology, and laboratory
evaluations.
Results: Three siblings, diagnosed at 14.7, 10.1, and 3.2 years of age, demonstrated clinical improvement with weekly
infusions of 2.0 mg/kg elosulfase alfa ( Vimizim®, BioMarin Pharmaceutical, Novato, CA, USA). Patient 1 (oldest sibling)
and Patient 2 (middle sibling) experienced a diagnostic delay of 8 years 7 months and 4 years after symptom onset,
respectively. All three patients demonstrated improvements in growth, 6-min walk distance, joint range of motion,
and respiratory function after 30 months of ERT. The treatment was well tolerated without any adverse events.
Conclusions: This case series highlights the importance of early recognition of the clinical and imaging findings
that are initially subtle in MPS IVA. Early treatment with ERT is necessary to slow irreversible disease progression and
improve patient outcomes. The oldest sibling experienced improvements in mobility despite severe symptoms resulting from a late diagnosis. When evaluating patients with skeletal anomalies, imaging multiple body regions is recommended. When findings such as anterior beaking of vertebrae or bilateral femoral head dysplasia are present, MPS IVA
should be included in the differential diagnosis. Newborn screening must be considered for early detection, accurate
diagnosis, and initiation of treatment to reduce morbidity.
Keywords: Mucopolysaccharidosis IVA, Enzyme replacement therapy, Anterior beaking, Platyspondyly, Diagnosis,
Treatment

*Correspondence: ficicioglu@email.chop.edu
1
Division of Human Genetics/Metabolism, Lysosomal Storage Diseases
Program, The Children’s Hospital of Philadelphia, Perelman School
of Medicine, The University of Pennsylvania, 3401 Civic Center Blvd.,
Philadelphia, PA 19104, USA
Full list of author information is available at the end of the article

Background
Mucopolysaccharidosis (MPS) IVA, also referred to as
Morquio A syndrome, is a rare autosomal recessive lysosomal storage disorder caused by a deficiency in the
enzyme N-acetylgalactosamine-6-sulfatase (GALNS)
[1–4]. Impaired degradation of the glycosaminoglycans
(GAGs) keratan sulfate and chondroitin 6-sulfate stemming from reduced GALNS activity results in undegraded GAGs in lysosomes across multiple tissues and
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organs, particularly in chondrocytes [3]. MPS IVA typically presents with bony abnormalities, short stature, and
skeletal dysplasia [3, 5, 6]. Other findings include respiratory insufficiency, cardiovascular abnormalities, and
dental impacts [5, 7]. Due to the progressive and heterogeneous nature of the disease and its variable presentation, early diagnosis can be challenging [1, 8]. However,
prompt recognition, accurate diagnosis, and proper management of the disorder are necessary to improve patient
outcomes [8].
Prior to the approval of elosulfase alfa 
( Vimizim®,
BioMarin Pharmaceutical, Novato, CA, USA) as an
enzyme replacement therapy (ERT) for patients with
MPS IVA [9, 10], the treatment of MPS IVA mainly consisted of supportive therapy [11]. In a randomized, double-blind, placebo-controlled phase 3 pivotal trial that
included patients ≥ 5 years of age, treatment with elosulfase alfa was well tolerated and resulted in a considerable improvement in endurance (6-min walk distance
[6MWD]), substantial reduction in urinary keratan sulfate, and improvements in pulmonary function, height,
and growth compared with placebo [11]. In a phase 2,
open-label study in patients younger than 5 years of
age, elosulfase alfa was well tolerated and resulted in a
reduction of urinary keratan sulfate and a trend toward
improvement in growth [12]. Previously published case
reports of siblings with MPS disorders have shown that
earlier treatment and management of these disorders
results in improved outcomes [13–15].
Evidence of the impact of treatment with ERT and
other interventions is needed to help inform healthcare
providers of the importance of early diagnosis and to support newborn screening initiatives. In this case report,
we describe three African American siblings who presented with similar symptoms at 5, 5, and 3 years of age,
respectively. The two older siblings experienced a delay in
diagnosis after the onset of symptoms, while the youngest sibling was suspected to have the same condition. The
diagnosis for all three siblings was confirmed as MPS
IVA via molecular genetic analysis and biochemical data.
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The differences in the siblings’ clinical courses highlight
the importance of early recognition of MPS IVA because
of the progressive nature of this disorder; specifically,
understanding and recognizing the skeletal abnormalities
of MPS IVA early will enable timelier diagnosis and treatment, which could help reduce mortality and morbidity.

Methods
The three siblings with MPS IVA presented at Children’s
Hospital of Philadelphia (CHOP) in the United States
for clinical care. The siblings were born to non-consanguineous parents. Parental consent was obtained from
both parents to use the patients’ medical data and photographs. All radiographs, magnetic resonance imaging
(MRI), genetic testing, and other results were performed
clinically and reviewed. All three patients initiated ERT
(elosulfase alfa, BioMarin Pharmaceutical Inc., Novato,
CA, USA) at the same time (Patient 1, 14.7 years of age;
Patient 2, 10.1 years of age; Patient 3, 3.2 years of age).
Results
Clinical manifestations and laboratory evaluations

The clinical course of the three siblings is summarized in Table 1. All patients presented with similar
symptoms at different ages. Patient 1 (oldest sibling)
was noted to have a limp and endorsed hip pain at
5 years of age; he was diagnosed with bilateral LeggCalve-Perthes disease (Fig. 1). At 7 years of age, he
was referred to orthopedics for further evaluation
and treatment at Children’s Hospital of Philadelphia
(CHOP). Upon examination at the clinic, he presented
with an abnormal wide gait with the lower legs placed
in valgus; tenderness on the bilateral greater trochanter; and full range of motion, but with mild tenderness, on both knees and ankles. He underwent hip
surgery and experienced a prolonged recovery with
worsening of his symptoms. After his recovery, he
was lost to follow-up and was seen again by orthopedics at CHOP at 11 years of age. At that time, he was
unable to walk independently and was noted to have

Table 1 Clinical course for Patients 1, 2, and 3 with MPS IVA
Patient 1

Patient 2

Patient 3

Current age

17 years, 8 months

13 years, 1 month

6 years, 2 months

Type of genetic analysis

Whole-exome sequencing

Whole-exome sequencing

Targeted GALNS sequencing

Results of GALNS gene analysis

c. 964G > C, p. A322P (paternally inherited, novel missense, variant of unknown significance)
c. 611A > G, p. N204S (maternally inherited, novel missense, variant of unknown significance)

Age at onset of symptoms

5 years

5 years

3 years

Age at diagnosis

14 years, 7 months

10 years

3 years, 1 month

Age at initiation of ERT

14 years, 8 months

10 years, 1 month

3 years, 2 months

ERT enzyme replacement therapy, MPS IVA mucopolysaccharidosis type IVA
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Fig. 1 Anteroposterior radiograph of hips and pelvis in Patient
1 at 6 years of age shows bilateral sclerotic, fragmented, and
flattened proximal femoral epiphyses (asterisks), irregular acetabula
(arrowheads), and coxa valga deformities. The patient was initially
diagnosed with Legg–Calve–Perthes disease; in retrospect, acetabular
irregularities and coxa valga would not be typical in this condition

a wide-based stance with increased weakness. Pelvis radiographs over time demonstrated progressive
destructive change of the hips (Fig. 2). His progressive
weakness prompted a referral to the neuromuscular
clinic, and electromyography findings were suggestive of mild myopathy. Radiographs and MRIs of the
spine revealed multiple abnormalities, with prominent
middle third spine vertebral involvement, consisting of prominent anterior beaking, posterior endplate
concavities, and mild platyspondyly (Fig. 3). Spondyloepiphyseal dysplasia was suspected due to the combination of proximal femoral epiphyseal abnormalities,
odontoid hypoplasia (Fig. 4), and platyspondyly, but
genetic sequencing and deletion/duplication studies of COL2A1 (collagen type II alpha 1) and SEDL
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(spondyloepiphyseal dysplasia tarda) were negative. In
retrospect, other radiographic features, including anterior vertebral beaking and metacarpal abnormalities
(Fig. 5), favored MPS IVA. At 5 years of age, Patient
2 (middle sibling) was noted to experience the same
pattern of clinical signs and symptoms as Patient 1.
A skeletal survey was completed, which showed symmetrically abnormal femoral heads, radial and ulnar
epiphyses, and carpal bones. Additionally, the lumbar
vertebrae were noted to be slightly flattened and bullet
shaped. Following diagnosis of the two older brothers,
Patient 3 (youngest sibling) was diagnosed through
family screening. The parents observed his wide-based
gait at around 2.5 years of age, but the symptom was
not brought to medical attention until diagnosis of his
older siblings.
Patients 1 and 2 were referred for whole-exome
sequencing at 14 and 9 years of age, respectively, which
revealed compound heterozygous variants in the GALNS
gene (Table 1). Enzyme testing revealed low GALNS
activity. Urine GAG quantification revealed elevated
GAGs, specifically chondroitin sulfate and keratan sulfate. Targeted-gene sequencing confirmed the diagnosis in Patient 3. Patient 3 was the least severely affected,
with subtle differences in his skeletal survey and presenting with a slightly abnormal gait. The numerous skeletal
abnormalities noted radiographically and reduced walking ability of Patient 1 highlight the progression of disease (Fig. 6).
The three siblings were started on intravenous infusions of elosulfase alfa at a dose of 2.0 mg/kg/week. The
progression of clinical signs, symptoms, and laboratory
studies in response to ERT after 30 months are summarized in Table 2.

Fig. 2 Representative serial radiographs of the proximal right femur of Patient 1 over time show progressive flattening of the epiphysis,
concomitant widening of the proximal metaphyses, and increased irregularity of the acetabula resulting in compensatory pseudarthrosis-like
formation
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Fig. 3 Lateral radiographs and MRIs of the thoracic spine in the three siblings. a In Patient 1, lateral thoracic spine radiograph (left) at 10 years of
age shows relatively moderate vertebral body height loss (platyspondyly) and anterior vertebral body beaking, most prominent in the mid-to-lower
thoracic spine (arrowheads). Sagittal T2-weighted MRI of the thoracic spine (right) shows moderate platyspondyly with prominent anterior beaking
of multiple thoracic and upper lumbar vertebral bodies (arrowheads). The patient was initially diagnosed with spondyloepiphyseal dysplasia on
the basis of clinical presentation, platyspondyly, and femoral epiphyseal abnormalities on imaging, although anterior beaking in the middle third of
the spine is highly suggestive of MPS IVA, and vertebral flattening is not as prominent as would be expected in spondyloepiphyseal dysplasia. b In
Patient 2, lateral thoracic spine radiograph at 6 years of age (left) shows anterior beaking of multiple thoracic vertebral bodies (arrowheads). Sagittal
T2-weighted MRI of the thoracic spine at 10 years of age (right) shows anterior vertebral body beaking (arrowheads) with mild vertebral height
loss without platyspondyly. Presence of anterior vertebral body beaking in this case is strongly suggestive of MPS IVA. c In Patient 3, lateral thoracic
spine radiograph at 3 years of age (left) shows anterior beaking of multiple thoracic vertebral bodies without significant vertebral body height loss.
Sagittal T2-weighted MRI of the thoracic spine at 5 years of age (right) highlights anterior vertebral body beaking. As with this patient’s siblings,
anterior vertebral body beaking supported the diagnosis of MPS IVA

Endurance

After undergoing 30 months of ERT, all three patients
showed an improvement in endurance, as measured by

the 6-min walk test (6MWT). After 5 months of treatment, Patient 1 was unable to walk without the use of a
walking aid and was only able to walk 50 m with the use
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and 3 were 265 m and 175 m, respectively, after 5 months
of ERT. The 6MWT distances increased to 425 m after
30 months for Patient 2 and 290 m after 15 months for
Patient 3.
Clinical measures of skeletal growth and function

Fig. 4 Sagittal T2-weighted TSE MRI of the cervical spine of Patient
1 at 10 years of age shows dysplastic odontoid process of C2, with
irregular sclerosis and posterior migration of the tip of the dens
(asterisk)

of bilateral forearm crutches during the 6MWT. However, after 30 months of ERT, Patient 1 was able to walk
unassisted for 300 m. The 6MWT results of Patients 2

The height, weight, and BMI of all three patients
increased from baseline after 30 months of ERT; of note,
the largest increase in percentiles for both weight and
height was found in Patient 3 (Table 2). Patient 1’s height
was 165.3 cm (7th percentile), and his weight was 65.3 kg
(51st percentile) 30 months after starting ERT. After
starting ERT, he gained weight (from the 39th percentile
to the 51st percentile), and his BMI increased (from 48th
percentile to the 78th percentile). Although he gained
4 cm, his height percentile was not preserved, decreasing from the 25th to the 7th percentile. Patient 2’s height,
weight, and BMI were preserved, with his height being
151.5 cm (43rd percentile), weight being 37.1 kg (20th
percentile), and BMI being 15.8 kg/cm2 (11th percentile) at 30 months post-treatment. Patient 3’s height was
116.4 cm (74th percentile), his weight was 27.3 kg (98th
percentile), and his BMI was 19.9 kg/cm2 (99th percentile) at 30 months post-treatment. The height percentile
of Patient 3 increased from the 60th to the 74th percentile, his weight increased from the 87th to the 98th percentile, and his BMI increased from the 91st to the 99th
percentile.
Joint range of motion (ROM) was assessed in
the hips, knees, and ankles. Patient 1 experienced

Fig. 5 Radiographic features of the hand in the three siblings supportive of MPS IVA. a Patient 1 at 6 years of age showed prominent shortening
of the fourth and fifth metacarpals (asterisks) with proximal pointing of the fifth metacarpal (arrowhead) and widening of the first metacarpal. b
Patient 2 at 6 years of age showed proximal pointing of the fifth metacarpal (arrowhead) and irregular carpal bones (asterisk). Notably, this patient’s
metacarpal abnormalities were much less conspicuous compared with those of his older brother (Patient 1) at the same age. c Patient 3 at 3 years
of age showed proximally shortened, widened metacarpals with proximal pointing of the second and fifth metacarpals (arrowheads)
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Fig. 6 Physical examination of the siblings. Patient 1 at 14 years of age, Patient 2 at 9 years of age, and Patient 3 at 3 years of age. Lordotic posture
can be noted in all three patients. Prior to starting ERT, all three siblings showed skeletal abnormalities and walking impairment, which were more
advanced in the oldest sibling (Patient 1)

improvement (> 5°) in bilateral hip abduction, left
hip internal rotation, bilateral knee extension, and
bilateral ankle dorsiflexion with the knee flexed after
5–30 months of ERT; right hip internal rotation
remained unchanged. In Patient 2, similar improvements were seen in left hip internal and external rotation, left ankle dorsiflexion with knee extended, and
bilateral popliteal angles after 5–30 months of ERT.
Improvements to right ankle dorsiflexion with knee
extended were minor (< 5°), and right hip rotation was
reduced (from 20° before ERT to 10° after 30 months
of ERT for internal rotation and from 30° before ERT
to 5° after 30 months of ERT for external rotation).
In Patient 3, bilateral ankle dorsiflexion with knee
extended ROM and bilateral popliteal angles improved
after 30 months of ERT.
Prior to initiation of ERT, Patient 1 was unable to
walk independently and unable to remain in standing
position. Improvement in mobility was observed after
30 months of ERT, with the patient being able to walk
without assistance for 300 m. Additional files 1 and 2
demonstrates this improvement in mobility.

Cardiopulmonary evaluation

Initial cardiac evaluation was performed using an
echocardiogram. There were no valve abnormalities or
structural defects identified, and both left and right ventricles were of normal size with normal systolic shortening for all three patients before the initiation of ERT.
There were no changes in their echocardiography findings or cardiac evaluations after 20 months of ERT.
Pulmonary function was evaluated using spirometry,
and results were available for Patients 1 and 2. Prior to
ERT, Patient 1 demonstrated 150% and 121% of predicted
value for forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1), respectively. After 20 months
of ERT, he had 157% and 121% of predicted value for
FVC and FEV1, respectively. Patient 1’s FEV1/FEV was
moderately increased and forced expiratory flow between
25 and 75% of FVC (FEF25–75) mildly decreased. Prior to
ERT, Patient 2 had 71% of predicted value for both FVC
and FEV1. After 20 months of ERT, his FVC and FEV1
predicted values increased to 85% and 78%, respectively.
His FEV1/FEV was moderately decreased and F
 EF25–75
was mildly increased. Patient 2 reported experiencing
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Table 2 Comparison of clinical signs, symptoms, and laboratory studies of the three siblings at baseline
and after 30 months of ERT
Patient 1

Patient 2

Patient 3

Before ERT

After ERT

Before ERT

After ERT

Before ERT

After ERT

6MWD,a m

50d

300

265

425

175f

290e

Height, cm
(percentileb)

161.4 (25)

165.3 (7)

137.5 (44)

153.1 (43)

97.0 (60)

117.2 (74)

Weight, kg
(percentileb)

50.8 (39)

65.3 (51)

27.9 (21)

37.1 (20)

16.6 (87)

27.3 (98)

BMI, kg/cm2
(percentileb)

19.5 (48)

23.9 (78)

14.8 (11)

15.8 (11)

17.6 (91)

19.9 (99)

–

–

R: 55

Joint ROM, a degrees
Hip abduction
Hip internal rotation
Knee extension

R: 10

R: 20e

R: 20

L: 15

L: 20e

L: 20

R: 10

e

R: 10

R: 30

R: 40

L: 5

L: 15e

L: 30

L: 10e

R: − 35

R: − 20

–

R: 0

R: 15e

–

L: − 55

Ankle dorsiflexion R: 8
with knee flexed L: 10
Ankle dorsiflexion with knee
extended

–

Popliteal angle

–

Cardiac functionc

No significant
findings

L: − 30

L: 55
e

L: − 15

–

–

R: 60
L: 60

–

R: 0

–

–

L: 0

L: 15e
R: 0

R: 8

R: 10

R: 10

R: 15

L: 5

L: 5

L: 10

L: 10

L: 15

–
–

R: 15

R: 25

R: 30

R: 0

L: 15

L: 35

L: 30

L: 0

No significant
findings

No significant
changes

No significant
findings

–

Respiratory function
FVC,c %

150

157

71

85

–

–

FEV1,c %

121

121

71

78

–

–

FEV1/FVCc

71

79

101

81

–

–

FEF25–75,c %

76

70

41

46

–

–

Snoring, no
evidence of
significant OSA

No evidence of
OSA or restrictive
lung disease

Normal breathing

No evidence of
OSA or restrictive
lung disease

Snoring, no evidence
of substantial OSA

Mild corneal haze

Mild corneal haze

Mild corneal haze

Mild corneal haze

Subtle corneal haze Diffuse fine corneal
haze

Chondroitin
sulfate, g/mol
creatinine

7.77

2.87e

9.61

8.01e

21.2

14.19e

Keratan sulfate,
μg/mol creatinine

5.35

2.97e

7.21

6.33e

16.6

9.95e

Polysomnography –

Ophthalmology
Urinary GAGs

6MWD 6-min walk distance, BMI body mass index, CDC US Centers for Disease Control and Prevention, ERT enzyme replacement therapy, FEF25–75 forced expiratory
flow between 25 and75% of FVC, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, GAGglycosaminoglycan, OSA obstructive sleep apnea, ROM range of
motion
a

Initial joint ROM and 6MWD evaluations were conducted after initiation of treatment (Patients 1 and 2, 5 months; Patient 3, 3 months)

b

CDC Clinical Growth Charts for 2–20 years of age

c

Evaluation after 20 months of ERT

d

Ambulation with bilateral forearm crutches in 59 s

e

Evaluation after 30 months of ERT

f

Distance walked in 2.75 min due to refusal to continue
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shortness of breath during activity and excessive daytime
somnolence when evaluated after 15 months of ERT. At
20 months of ERT, polysomnography showed snoring
with no evidence of significant obstructive sleep apnea in
Patients 1 and 3. Patient 2 had normal breathing during
sleep.
Ophthalmology

Both Patient 1 and Patient 2 had bilateral mild corneal
haze prior to ERT, which remained unchanged after
30 months of ERT. In Patient 3, bilateral subtle corneal haze improved to diffuse, fine corneal haze after
30 months of ERT.
Urinary glycosaminoglycan levels

In all three patients, urinary chondroitin sulfate (g/
mol creatinine) and keratan sulfate (μg/mol creatinine)
decreased with ERT (Table 2).
ERT dosage and adverse reactions

All three patients received weekly infusions of elosulfase
alfa at a dose of 2.0 mg/kg, and treatment was well tolerated throughout its duration without any adverse events.
Clinical course of the three patients with MPS IVA

Patients with MPS IVA usually present with clinical signs
or symptoms at the end of the first year of life. Most
who present with classical symptoms are diagnosed at
2–3 years of age due to disproportional short stature,
waddling gait, pectus carinatum, and frequent respiratory infections.
Diagnostic delay: Patient 1 presented with limp and
hip pain around 5 years of age. He was seen by orthopedics at an outside institution and diagnosed with bilateral Legg-Calve-Perthes disease of unknown etiology.
He was referred to orthopedics at the CHOP at 7 years
of age, where a work-up for Legg-Calve-Perthes disease
was undertaken and tested negative, including normal
alpha globin, prothrombin, and Factor V Leiden genetic
testing. His orthopedic surgeon questioned the diagnosis
and referral to neuromuscular was recommended, given
the progression of his symptoms and weakness. However,
due to insurance issues, a consultation was not completed, and the patient was lost to follow-up for several
years. He re-presented to care when his younger brother
(Patient 2) developed the same symptoms. Further evaluation of the case by a neurologist and clinical geneticist
lead to sending for whole-exome sequencing, which
revealed compound heterozygous variants in the GALNS
gene. In this case, the protracted diagnostic odyssey was
likely due to the initial subtlety of findings and lack of
knowledge about symptoms and signs of this rare, inherited metabolic disease among many physicians. Typically,
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disproportionately short stature has been considered a
hallmark of this disorder. In this case series, Patients 1
and 2 were initially of normal height. Thus, a high index
of suspicion and diligent examination of radiographs is
required.
Treatment response: Patient 1 was severely affected at
the time of diagnosis. He was unable to stand up without assistance and only capable of taking a few steps with
assistance. After starting ERT, his endurance improved,
and he was able to stand up independently; after
6 months of therapy, he started walking with crutches.
One year after starting ERT, he started walking unassisted. Video 1 highlights his ability to walk unassisted
during the 6MWT. His 6MWD increased significantly.
His urine GAGs decreased, and his cardiac, pulmonary,
and ophthalmological findings were stable. Due to the
late diagnosis and severe skeletal involvement, his height
increased only 4 inches in 30 months on ERT.
Patient 2 presented with a wide-based gait and hip pain
at around 5 years of age. His symptoms remained more
or less stable for the next 4 years, although each year, he
had increased difficulty with walking. When he was diagnosed at 9 years of age, his 6MWD was 265 m, which
increased to 425 m after 30 months of ERT. His walk is
shown in Video 2. His height remained preserved around
the 40th percentile.
Patient 3 was 3 years old at the time of diagnosis
through family screening. Parents recalled that they
noticed a wide-based gait beginning at around 2.5 years
of age but were not concerned until his older brothers were diagnosed with MPS IVA. His waddling gait
remained stable after the ERT. His 6MWD increased
from 175 to 290 m, but the accuracy of this measurement was compromised because of poor cooperation.
His height increased from the 60th to the 74th percentile.

Discussion
The efficacy and safety of elosulfase alfa in treating MPS IVA have previously been demonstrated in
patients ≥ 5 years and < 5 years of age. In this report,
three siblings with MPS IVA initiated weekly infusions of
elosulfase alfa starting at 14.7, 10.1, and 3.2 years of age,
respectively. Thirty months of ERT was well tolerated and
led to improvements in endurance (6MWD), growth, and
joint ROM, and reduction in urinary GAGs, consistent
with prior clinical studies.
Early diagnosis of MPS IVA is important to initiate
treatment with ERT as soon as possible, as skeletal manifestations are considered irreversible. In this report, the
three siblings received ERT at different stages of MPS
IVA; Patient 1 had the most-severe presentation and
was unable to walk independently at the start of treatment, whereas Patients 2 and 3 have developed some
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radiographic features of MPS IVA but have not yet experienced severe impairment to their mobility. While all
three patients experienced improvement in clinical outcomes after 30 months of ERT, Patient 1 showed remarkable improvement in being able to walk unassisted,
albeit not to the same level of his siblings who initiated
treatment earlier. These three cases show us that ERT
can reverse some progressive symptoms while slowing
others.
The clinical presentation of MPS IVA is heterogeneous,
and initial findings are subtle. This makes the diagnosis
a challenge and can lead to substantial delays, as underscored by the diagnostic journey of Patient 1 [1, 8]. This
case series highlights the importance of early recognition
of the clinical and imaging findings of MPS IVA, especially considering the progressive nature of this disorder.
The characteristic, progressive radiographic features in
the pelvis, spine, and hand, as documented in this study,
are key for MPS IVA diagnosis and follow-up testing.
Thus, when evaluating patients with skeletal anomalies,
imaging multiple body regions is recommended. With
findings such as anterior beaking of vertebrae or bilateral
femoral head dysplasia, MPS IVA should be included in
the differential, as early treatment can reduce morbidity.
Despite the three siblings initially presenting with
similar signs and symptoms, Patient 1 had a more-severe
functional disability due to 9-year diagnostic delay.
Improving awareness and recognition of MPS IVA will
enable earlier diagnosis and treatment [8]. Evidence- and
consensus-based management guidelines for MPS IVA
for healthcare professionals have recommended implementation of newborn screening for MPS IVA to allow
very early ERT to help slow the progression of the disease
and improve outcomes [1]. Long-term ERT (elosulfase
alfa, 2.0 mg/kg weekly IV infusions) is recommended in
all patients with a confirmed MPS IVA diagnosis [1].

Conclusion
Treatment with elosulfase alfa ERT in three siblings
with MPS IVA was effective in improving clinical outcomes and was well tolerated. The variable clinical
presentation, delay in diagnosis, and progressive nature
of MPS IVA, as demonstrated by these three siblings,
highlight the importance of improving awareness and
recognition of the disease’s early signs and symptoms.
The initiation of ERT in these siblings improved their
endurance, reduced their pain, and improved their
ranges of motion. In the younger siblings, height was
preserved or improved. Additionally, in the youngest
sibling, ophthalmologic findings improved. The youngest and middle siblings continue to walk independently,
and the oldest sibling can now walk with crutches or
unassisted for 300 m. This highlights the substantial
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effect of ERT in slowing disease progression and
improving patient outcomes even in the late-diagnosed
patient. Newborn screening for MPS IVA is necessary
to prevent diagnostic delay and initiate treatment as
early as possible to achieve better clinical outcomes.
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